First Human Trial of Alzheimer's Nasal Vaccine To Prevent And Slow Disease
- 'First human trial of Alzheimer's disease nasal vaccine to begin at Boston hospital,' CBS News, Nov. 16, 21
Brigham and Women's Hospital will test the safety and efficacy of a nasal vaccine aimed at preventing and slowing Alzheimer's disease, the Boston hospital announced Tuesday. The start of the small, Phase I clinical trial comes after nearly 20 years of research led by Howard L. Weiner, MD, co-director of the Ann Romney Center for Neurologic Diseases at the hospital.
The trial will include 16 participants between the ages of 60 and 85, all with early symptomatic Alzheimer's but otherwise generally healthy. They will receive two doses of the vaccine one week apart, the hospital said in a press release. The participants will enroll from the Ann Romney Center.
A Phase I clinical trial is designed to establish the safety and dosage for a potential new medication. If it goes well, a much larger trial would be needed to test its effectiveness.
https://www.cbsnews.com/news/alzheimers-disease-nasal-vaccine-human-trial-to-begin-at-boston-hospital/